Segmentation, Major Trends, and Competitive Overview of the Cancer Gene Therapy Market

The field of cancer gene therapy is rapidly evolving, offering new hope for more effective and personalized treatment options. As advancements continue, the market is set to undergo significant expansion driven by technological progress and growing clinical demand. Below is an in-depth look at the market size, key players, emerging trends, and segmentation within this promising sector.

Projected Growth and Market Size of the Cancer Gene Therapy Industry
The cancer gene therapy market is anticipated to experience substantial growth in the coming years, reaching a valuation of $8.9 billion by 2030. This reflects a robust compound annual growth rate (CAGR) of 16.1%. Several factors contribute to this positive outlook, including the rising need for personalized cancer treatments, increasing investments in cell and gene therapy manufacturing infrastructure, advancements in next-generation viral vectors, and an expanding focus on combination oncology therapies. Additionally, precision oncology approaches are becoming more widely adopted, further fueling market growth. Important trends during this period include the development of targeted gene therapy platforms, growing use of CAR-T and TCR therapies, ongoing optimization of viral vectors, the expansion of personalized cancer gene treatments, and greater incorporation of biomarker-guided therapy selection.

Download a free sample of the cancer gene therapy market report:
https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Players Influencing the Cancer Gene Therapy Market
The cancer gene therapy landscape is shaped by numerous leading companies, such as Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, and Caribou Biosciences Inc. A notable recent development took place in May 2025 when AstraZeneca plc, a UK-based biopharmaceutical firm, acquired EsoBiotec B.V., a Swiss biotechnology company specializing in cancer gene therapies. This acquisition aims to boost AstraZeneca's cell therapy capabilities and accelerate its ambitions in next-generation oncology and immune-mediated disease treatments.

Emerging Trends in Cancer Gene Therapy Driving Innovation
Leading firms in the field are concentrating on creating innovative formulations that improve patient experience and therapeutic outcomes. One such focus is on non-invasive glucose monitoring technologies, which enhance metabolic tracking without the discomfort of traditional blood draws. These advancements not only improve real-time monitoring but also facilitate better management of chronic diseases like diabetes.
For example, in June 2024, Abbott Laboratories partnered with Dexcom, Inc., to launch the first over-the-counter continuous glucose monitors (CGMs). These devices provide real-time glucose readings via a smartphone app, eliminating the need for finger pricks. They offer enhanced accuracy, longer wear times, and seamless connectivity, making them valuable tools for diabetic patients as well as health-conscious individuals seeking personalized metabolic insights.

The field of cancer gene therapy is rapidly evolving, offering new hope for more effective and personalized treatment options. As advancements continue, the market is set to undergo significant expansion driven by technological progress and growing clinical demand. Below is an in-depth look at the market size, key players, emerging trends, and segmentation within this promising sector.

Projected Growth and Market Size of the Cancer Gene Therapy Industry
The cancer gene therapy market is anticipated to experience substantial growth in the coming years, reaching a valuation of $8.9 billion by 2030. This reflects a robust compound annual growth rate (CAGR) of 16.1%. Several factors contribute to this positive outlook, including the rising need for personalized cancer treatments, increasing investments in cell and gene therapy manufacturing infrastructure, advancements in next-generation viral vectors, and an expanding focus on combination oncology therapies. Additionally, precision oncology approaches are becoming more widely adopted, further fueling market growth. Important trends during this period include the development of targeted gene therapy platforms, growing use of CAR-T and TCR therapies, ongoing optimization of viral vectors, the expansion of personalized cancer gene treatments, and greater incorporation of biomarker-guided therapy selection.

Download a free sample of the cancer gene therapy market report:
https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Players Influencing the Cancer Gene Therapy Market
The cancer gene therapy landscape is shaped by numerous leading companies, such as Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, and Caribou Biosciences Inc. A notable recent development took place in May 2025 when AstraZeneca plc, a UK-based biopharmaceutical firm, acquired EsoBiotec B.V., a Swiss biotechnology company specializing in cancer gene therapies. This acquisition aims to boost AstraZeneca's cell therapy capabilities and accelerate its ambitions in next-generation oncology and immune-mediated disease treatments.

Emerging Trends in Cancer Gene Therapy Driving Innovation
Leading firms in the field are concentrating on creating innovative formulations that improve patient experience and therapeutic outcomes. One such focus is on non-invasive glucose monitoring technologies, which enhance metabolic tracking without the discomfort of traditional blood draws. These advancements not only improve real-time monitoring but also facilitate better management of chronic diseases like diabetes.
For example, in June 2024, Abbott Laboratories partnered with Dexcom, Inc., to launch the first over-the-counter continuous glucose monitors (CGMs). These devices provide real-time glucose readings via a smartphone app, eliminating the need for finger pricks. They offer enhanced accuracy, longer wear times, and seamless connectivity, making them valuable tools for diabetic patients as well as health-conscious individuals seeking personalized metabolic insights.

Breakdown of Segments within the Cancer Gene Therapy Market
This market is segmented based on therapy type, indications, vector types, and end-user categories. The therapy segment includes Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Indications covered encompass Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma lesions, and other cancer types. Vector types include Lentivirus, Retrovirus and Gamma Retrovirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, and other vector varieties. End-users consist of Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, and other users.
Further subsegments detail specific therapies such as CAR-T Cell Therapy, TCR Therapy, Tumor-Infiltrating Lymphocyte Therapy, Dendritic Cell-Based Gene Therapy, and NK Cell Gene Therapy under Gene Induced Immunotherapy. Oncolytic Virotherapy includes Adenoviruses, Herpes Simplex Virus, Reovirus, Vaccinia Virus, and Newcastle Disease Virus. Gene Transfer is divided into Viral and Non-Viral approaches, offering a comprehensive view of this intricate market landscape.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.